|Awarded On||February 15, 2023|
|Title||Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Melanie Bernhardt|
Latino children are more likely to be diagnosed with acute lymphoblastic leukemia (ALL) compared to non-Latino children and more likely to have high risk disease, experience a relapse, or die due to leukemia. Sadly, this is even more apparent in Texas and across the Southwestern United States, where most newly diagnosed patients with ALL are Latino. Latino children are also more likely to have severe side effects from medicines used to treat ALL. At Texas Children's Cancer Center, we found that Latino children are more likely to have severe side effects from methotrexate, one of the most important medicines to treat ALL. If a patient has severe side effects, the pediatric oncologist may need...